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Late-onset cytomegalovirus (CMV) disease remains
common in CMV serology naı̈ve kidney transplant pa-
tients of CMV serology positive organs (D+/R–) despite
the use of antiviral prophylaxis. We studied clinical ef-
ficacy of 6-month low-dose valganciclovir (VGCV) pro-
phylaxis, risk factors for late-onset CMV disease and its
impact on kidney transplant outcomes. Between Octo-
ber 2005 and December 2009, 166 consecutive D+/R–
kidney alone and simultaneous pancreas and kidney
transplant patients received VGCV 450 mg daily for
6 months after transplantation. After a median follow-
up of 3.2 years, 30 cases of CMV disease occurred
within the first 2 years after transplantation with a cu-
mulative incidence of 11.5 and 18.1% at 1 and 2 years,
respectively. The use of an induction agent with rabbit
antithymocyte globulin and older donor age were fac-
tors associated with the risk of late-onset CMV disease
(AHR 2.91, 95% CI 1.18–7.20, p = 0.021 and AHR 1.03,
95% CI 1.01–1.06, p = 0.016, respectively). Late-onset
CMV disease was associated with increased risk for
death-uncensored graft loss (AHR 2.95, 95% CI 1.15–
7.61, p = 0.025). In conclusion, late-onset CMV disease
continues to negatively impact kidney transplant out-
come despite 6-month low-dose VGCV prophylaxis. In-
vestigations focusing on novel preventive approaches
should be emphasized.
Key words: Cytomegalovirus, D+/R–, graft loss,
late-onset, prophylaxis, valganciclovir
Abbreviations: AA, African American; AHR, adjusted
hazard ratio; AOR, adjusted odds ratio; CI, confidence
interval; CMV, cytomegalovirus; CNI, calciuneurin in-
hibitor; CrCl, creatinine clearance by Cockcroft-Gault
equation; CsA, cyclosporine; D+/R–, donor CMV serol-
ogy positive and recipient CMV serology negative
combination; DGF, delayed graft function; ECD/DCD,
expanded criteria donor/donation after cardiac death;
G-CSF, granulocyte colony stimulating factor; GCV,
ganciclovir; HCV, hepatitis C virus; MMF, mycophe-
nolate mofetil; PCR, polymerase chain reaction; PRA,
panel reactive antibodies; rATG, rabbit antithymocyte
globulin; Tac, tacrolimus; VGCV, valganciclovir.
Received 01 February 2011, revised 25 April 2011 and
accepted for publication 28 April 2011
Introduction
With the widespread adoption of universal prophylaxis in
cytomegalovirus (CMV) serology naı̈ve organ transplant re-
cipients of serology positive organs (D+/R–), late-onset
CMV disease, defined as the occurrence of CMV disease
after the cessation of prophylaxis, remains as a concern
(1–4). CMV disease can cause significant morbidity, in-
creases mortality and is associated with inferior transplant
outcomes, particularly, in kidney transplantation (5–7).
Valganciclovir (VGCV) is an effective anti-CMV drug used in
the prevention and treatment of CMV disease in solid organ
transplant recipients (1,8). A recently completed random-
ized study has shown clinical benefit of prolonged VGCV
prophylaxis up to 200 days after transplantation in D+/R–
kidney transplant patients (4). Nevertheless, late-onset
CMV disease continues to affect 21–37% of D+/R– kid-
ney transplant patients within 2 years after transplantation
(9,10). The routinely recommended dose of VGCV for pro-
phylaxis is 900 mg daily based on the original clinical trial
(1). However, in clinical practice, a dose of 450 mg daily
is frequently used (11–14). Yet, there are only few re-
ports of clinical efficacy of low-dose VGCV on late-onset
CMV disease in D+/R– kidney transplant population, most
with a relatively short follow-up period (13,15). A recent
meta-analysis suggested that the clinical efficacy of uni-
versal prophylaxis with VGCV either 900 mg or 450 mg
daily was similar (16). Furthermore, it remains unknown
whether late-onset CMV disease negatively impacts pa-
tient and graft outcome in D+/R– kidney transplant patients
receiving extended low-dose VGCV prophylaxis.
This study is based on a single center experience involving
D+/R– kidney alone (KA) and simultaneous pancreas and
kidney (SPK) transplant patients who received low-dose
VGCV for 6 months following transplantation. This retro-
spective study aims to assess clinical efficacy and safety
of such regimen in the prevention of late-onset CMV dis-
ease and to identify potential risk factors as well as effects
on patient and graft outcomes associated with late-onset
CMV disease.
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Materials and Methods
All D+/R– KA and SPK transplant patients from October 1, 2005 to De-
cember 31, 2009 who survived through at least the period of prophy-
laxis with a functioning kidney graft were included. All patients received
prophylaxis with VGCV 450 mg daily, if their creatinine clearance (CrCl)
was equal or greater than 60 mL/min, for 6 months after transplantation.
A dose reduction was required if CrCl was lower than 60 mL/min such
that VGCV 450 mg every other day was given for patients with CrCl be-
tween 25 and 59 mL/min, VGCV 450 mg twice weekly for patients with
CrCl below 25 mL/min, and VGCV 450 mg three times a week after each
hemodialysis treatment for patients who experienced initial delayed graft
function. Patients were followed up to the time of graft loss, death or
December 31, 2010. The study was approved by the institutional review
board (IRB).
Immunosuppression regimens, including induction and maintenance, were
provided according to the institutional protocols. For induction regimen, rab-
bit antithymocyte globulin (rATG; Thymoglobulin R©, Genzyme, Cambridge,
MA, USA) or basiliximab, an anti-IL-2 receptor antibody (Simulect R©, Novar-
tis, East Hanover, NJ, USA) were utilized where dictated by the specific
center protocols. More specifically, patients with panel reactive antibodies
(PRAs) titer equal or greater than 20, African American racial identifica-
tion, living unrelated kidney transplant or pancreas transplant were given
rATG whereas patients with delayed or slow graft function were given
basiliximab. For maintenance immunosuppression, a triple drug regimen
which consisted of a calcineurin inhibitor (CNI; cyclosporine or tacrolimus),
an antiproliferative agent (mycophenolate mofetil—MMF or others) and
prednisone was usually used. Target trough levels for cyclosporine (CsA)
and tacrolimus (Tac) were 150–300 and 4–15 ng/mL, respectively, during
the first 3 months. Subsequently, CsA and Tac trough levels were main-
tained at 100–200 and 4–8 ng/mL, respectively. Prednisone was tapered to
10 mg/day at about 8 weeks posttransplant and remained at 5–10 mg daily
thereafter over the study period.
The primary endpoints were the incidence of late-onset CMV dis-
ease and kidney graft loss, censored and uncensored for death,
respectively.
The diagnosis of CMV disease was based on a constellation of symp-
toms and positive CMV DNA viremia determination using polymerase
chain reaction (PCR) technique during the entire duration of follow-up.
CMV/PCR testing was requested based upon clinical suspicion by trans-
plant physicians. The test was performed on the platform of COBAS Am-
plicor instrument with all reagents purchased from the Roche Diagnostics
(Indianapolis, IN, USA). The most common clinical suspicions for order-
ing such determination were gastroenteric symptoms, viral like symptoms
such as fever and malaise or the presence of leukopenia, particularly neu-
tropenia. The tissue diagnosis to document the presence of tissue inva-
sion was obtained in some patients on a case-by-case basis as deter-
mined by physicians. Patients with a positive CMV DNA viremia, with
or without symptoms, were treated with an additional course of either
intravenous ganciclovir (GCV) or oral VGCV and temporary discontinua-
tion of antiproliferative agents for up to 2–3 weeks (induction therapy
phase).
The secondary endpoint was the incidence of leukopenia and/or neutrope-
nia, the only adverse effect of prophylaxis considered, defined as peripheral
blood leukocyte and neutrophil counts of less than 4000/lL and 1400/lL,
respectively. The lowest leukocyte and neutrophil counts were recorded dur-
ing the initial 6 months after transplantation. The management of leukope-
nia/neutropenia, including the use of granulocyte colony stimulating factor
(G-CSF) was documented.
Student’s t-tests and v 2 tests were used to compare continuous and cate-
gorical variables, respectively, for baseline demographic and clinical charac-
teristics between patients with and without late-onset CMV disease. The
Kaplan–Meier method was used to estimate the incidence of late-onset
CMV disease during the study period. A generalized estimating equation
(GEE) model based on the Poisson distribution was utilized to compare
the cumulative incidence rate of kidney graft loss between patients with
and without late-onset CMV disease. Multivariate Cox proportional hazard
regression analysis was used to assess the effects of late-onset CMV dis-
ease on kidney graft loss and to identify the risk factors associated with
late-onset CMV disease. In order to account for changes in disease sta-
tus during the follow-up period, late-onset CMV disease was included as
a time-dependent covariate. In this way, patients were allowed to con-
tribute time at risk to the disease-free group until the time of disease
diagnosis, at which point they switched to the disease group. Initial model
selection was via backward selection. Because overfitting was a concern
in the Cox models, models were further reduced with the goal of opti-
mizing the Bayesian Information Criteria (BIC) (17). Multivariate logistic re-
gression analyses were performed investigating factors associated with
leukopenia.
Analyses were performed using SAS 9.2, with statistical significance set at
a two-sided a ≤ 0.05.
Results
A total of 182 consecutive CMV D+/R– KA and SPK trans-
plant patients were identified initially as meeting inclusion
criteria for the study. The median follow-up was 3.2 years
from the time of transplant with range between 1 and 5
years. A mean of 3.8 ± 4.2 diagnostic CMV viremia deter-
minations per patient was carried out during the study pe-
riod and 30 patients (16.5%) were found to have developed
late-onset CMV disease within the first 2 years after trans-
plantation. An additional 16 patients (8.8%) were found to
have positive CMV DNA viremia without symptoms sug-
gestive of disease. Due to the lack of systematic viremia
monitoring during the entire study period, these 16 cases
of asymptomatic CMV infection could represent an un-
derestimated phenomenon with possibly different clinical
implication and were thus excluded from further analyses
(1,18,19).
Of 30 patients with late-onset CMV disease, 22 had proba-
ble or confirmed CMV gastroenteric disease (fever, abdom-
inal pain, vomiting and diarrhea at presentation, only four
patients had a tissue diagnosis through endoscopic proce-
dures) with or without signs of hepatitis and pancreatitis,
and eight had CMV syndrome. The cumulative incidence of
late-onset CMV disease was 11.5% at 1 year and 18.1%
at 2 years after transplantation, respectively (Figure 1A).
The median time to CMV disease was 293 days from the
time of transplant with a range from 114 to 639 days post-
transplant. Four patients developed CMV disease during
the period of prophylaxis. A careful chart review revealed
that two patients had their VGCV on hold for more than
1 month (for leukopenia/neutropenia) and other two pa-
tients had their dose of VGCV reduced to twice and thrice
weekly, respectively, due to reduced renal function, prior to
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Figure 1: Kaplan–Meier late-onset
CMV disease-free survival: (A)
among all patients; (B) stratified
by the use of different induction
regimens.
the diagnosis. Furthermore, another five patients (16.7%)
had recurrent CMV viremia requiring additional courses of
antiviral treatment. CMV resistance was not detected in
any of these cases.
Demographic and baseline clinical characteristics of pa-
tients with and without late-onset CMV disease are pre-
sented in Table 1. Patients were comparable with regard to
the majority of baseline characteristics including recipient
age, gender, positive hepatitis C (HCV) serology, the use
of expanded criteria donor or donation after cardiac death
kidneys (ECD/DCD) and incidence of delayed graft function
and acute rejection. The only baseline variables that were
significantly different between patients with and without
late-onset CMV disease are the differential use of induc-
tion regimens, donor age and the numbers of CMV/PCR
determination per patient. In fact, patients who developed
late-onset CMV disease were given induction more fre-
quently with rATG (73.3% vs. 47.0%, p = 0.02), received
more often kidney from older donors (44.0 ± 14.5 vs.
37.1 ± 15.0 years, p = 0.02) and had more CMV/PCR
tests per patient (8.7 ± 8.0 vs. 2.6 ± 1.6, p < 0.001).
We further studied the effects of induction on the devel-
opment of late-onset CMV disease in this cohort of pa-
tients. Six of 56 patients (10.7%) with no induction, 2 of
24 patients (8.3%) with basiliximab induction and 22 of
86 patients (25.6%) with rATG induction developed late-
onset CMV disease during the study period (Figure 1B).
All five patients with recurrent CMV viremia received in-
duction with rATG. Multivariate Cox proportional hazard
regression analysis with the use of backward selection
demonstrated that the use of rATG, but not basiliximab,
was associated with a statistically significant increase in
the risk for late-onset CMV disease (AHR 2.91, 95% CI
1.18–7.20, p = 0.021). The only other variable associated
with an increased risk for late-onset CMV disease is donor
age, as a 1-year increase in donor age was associated with
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N = 30 p
Recipient age, years
(SD)
46.1 (11.9) 46.5 (14.6) 0.87
Recipient gender, male,
n (%)
97 (71.3) 23 (76.7) 0.55
Recipient race, AA, n
(%)
16 (11.8) 5 (16.7) 0.46
HCV positive serology,
n (%)
6 (4.4) 1 (3.3) 1.00
Acute rejection, n (%) 0.75
Banff 1a or less 16 (11.8) 4 (13.3)
Banff 1b or higher 12 (8.8) 1 (3.3)
PRA, n (%) 0.06
< 10 110 (80.9) 21 (70.0)
10 – 80 24 (17.6) 6 (20.0)
> 80 2 (1.5) 3 (10.0)
Induction, n (%) 0.02
None 50 (36.8) 6 (20.0)
rATG 64 (47.0) 22 (73.3)
basiliximab 22 (16.2) 2 (6.7)
CNIs, Tac, n (%) 28 (20.6) 8 (26.7) 0.46
Living donor, n (%) 51 (37.5) 14 (46.7) 0.35
Donor age, years (SD) 37.1 (15.0) 44.0 (14.5) 0.02
Donor gender, male, n
(%)
73 (53.7) 11 (36.7) 0.09
Pancreas and kidney
transplant, n (%)
12 (8.8) 2 (6.7) 0.70
First transplant, n (%) 123 (90.4) 26 (86.7) 0.65
Diabetes mellitus, n
(%)
47 (34.6) 10 (33.3) 0.90
CrCl, mL/min. (sd) 77.2 (19.9) 72.8 (23.5) 0.35
CMV PCR test per
patient, n (SD)
2.6 (1.6) 8.7 (8.0) <0.001
3% higher risk of late-onset CMV disease (AHR 1.03, 95%
CI 1.01–1.06, p = 0.016).
During the study period, there were 19 kidney graft losses
including seven deaths with functioning graft. The inci-
dence rate was significantly higher among patients with
late-onset CMV disease than without late-onset CMV dis-
ease (12.3 cases vs. 2.7 cases per 100 person-years for
uncensored graft loss, p = 0.001, and 12.3 cases vs. 1.1
cases per 100 person-years for death censored graft loss,
p < 0.001, respectively; Figure 2). Multivariate analysis us-
ing late-onset CMV disease as a time-dependent covariate
suggested increased hazards for graft loss among patients
with late-onset CMV disease (AHR 2.95, 95% CI 1.15–
7.61, p = 0.025 for uncensored graft loss, and AHR 7.50,
95% CI 2.32–24.30 p < 0.001 for death censored graft
loss). Other risk factors associated with increased hazards
for graft loss included lower baseline renal function and
older recipient age (uncensored only; Table 2).
Finally, we assessed the safety aspect of 6 months prophy-
laxis with low-dose VGCV. One of the major adverse effects
related to the use of VGCV is bone marrow suppression,
manifested most frequently as leukopenia/neutropenia. Of
166 patients, 105 patients (63.3%) experienced at least
one episode of leukopenia during the period of prophylaxis.
Among them, 49 patients (46.7%) had neutrophil counts
of less than 1400/lL necessitating the use of G-CSF (fil-
grastim) in 18 patients. Otherwise, patients were managed
with temporary reduction or discontinuation of antiprolifer-
ative agents, and occasionally of VGCV, by individual caring
physicians. Logistic regression analyses identified the use
of rATG (AOR 3.49, 95% CI 1.55–7.85, p = 0.003) and
African American race (AOR 18.6, 95% CI 2.34–147.7,
p = 0.006) as two risk factors that were individually
and independently associated with the development of
at least one episode of leukopenia during the period of
prophylaxis.
Discussion
CMV disease and/or infection were associated with poor
clinical outcome among kidney transplant patients (5,6,19).
The use of universal prophylaxis appeared to improve the
clinical outcome and was thus recommended, particularly
for D+/R– patients (20–24). Nonetheless, late-onset CMV
disease remains common affecting 21–36% of D+/R– kid-
ney transplant patients despite the use of prophylaxis
(7,9,25). The similar clinical efficacy of VGCV 900 mg daily
compared to oral GCV 1000 mg three times daily has es-
tablished its role in the prevention of primary CMV infection
in the field of solid organ transplantation (1). However, the
optimal duration of prophylaxis of VGCV remains a matter
of debate, despite the fact that a recently completed clin-
ical trial has demonstrated the additional benefit in reduc-
ing late-onset CMV disease with longer duration of VGCV
prophylaxis at 900 mg daily (4,16,25,26). Little is known
about the clinical efficacy of 6-month low-dose VCGV at
450 mg daily, a dose frequently used in the clinical prac-
tice, in preventing late-onset CMV disease and in reduc-
ing the deleterious effects of CMV disease on graft loss.
The drug exposure of VCGV 450 mg daily was similar or
higher than that achieved by oral GCV 1000 mg three times
daily (12–15,27). Our study thus provides evidence of clin-
ical efficacy of low-dose VGCV at 450 mg daily given for 6
months in preventing late-onset CMV disease in D+/R– KA
and SPK transplant patients. Although a direct comparison
between our study and other studies including a recently
completed randomized clinical trial cannot be made and
was not the objective of our study for obvious reasons,
the cumulative incidence rate of 11.5% and 18.1% at 1
and 2 years is lower than what was reported in various
studies in which a dose of VGCV 900 mg daily was used
for 200 days or 6 months (4,9,25). Whether such differ-
ence is of any clinical significance or related to the fact of
using lower dose of valganciclovir is beyond our specula-
tion. On the other hand, our results pointed out persistent
deleterious effects of late-onset CMV disease on kidney
transplant outcome despite 6 months prophylaxis. Further-
more, after a median follow-up of 3.2 years, we did not
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Figure 2: Cumulative incidence of
kidney graft loss (overall and death
censored) between patients with
and without late-onset CMV dis-
ease. ∗Upper limit of 95% CI.
detect new cases of disease beyond 2 years from the date
of transplantation.
CMV infection is one of the most common opportunistic
infections following kidney transplantation. Previous stud-
ies, where no prophylaxis or prophylaxis for 3 months
were used, have shown deleterious effects of CMV dis-
ease and/or infection on the clinical outcome of kidney
transplantation, including reduced graft survival, increased
economic burden and shortened patient life (6,7,13,20).
Patients with CMV D+/R– serology combination repre-
sent the highest risk and the use of universal prophy-
laxis has been recommended for this group of patients
by various guidelines (3,24,28). The duration of prophy-
laxis varies although increasing evidence suggests that
longer is better (4,13,15). However, the incidence of late-
onset CMV disease remains unacceptably high (4,9). This
phenomenon could be partly caused by increasing use of
induction agents, particularly, T-cell depleting antibodies,
such as rATG (29–31). Our study further confirmed that
such negative effect of rATG persists despite prolonged
period of prophylaxis as 2 years cumulative incidence of
late-onset CMV disease was more than two and a half folds
higher among patients with than without the use of rATG
induction (25.6% vs. 10.5%).
Leukopenia, in particular neutropenia, is a well-known ad-
verse effect related to the use of valganciclovir. We report
63.3% incidence of at least one episode of leukopenia dur-
ing the period of prophylaxis which is higher than that re-
ported by the Impact study despite the fact that we used
lower dose of valganciclovir (4). There are several possi-
ble explanations, including a slightly different definition of
leukopenia used between our study and that of the Impact
study, different use in rATG, and/or difference in frequency
of laboratory testing leading to overdetection in our patient
population. Nevertheless, leukopenia remains common in
our study population with 10.8% of patients requiring
administration of G-CSF (filgrastim).
The major strengths of our study rely on the sample size,
which to the best of our knowledge, is one of the largest
involving only D+/R– KA and SPK transplant recipients,
sizable cases with late-onset CMV disease and long du-
ration of follow-up. In addition, in our study, the diagno-
sis of late-onset CMV disease was uniformly confirmed
through the determination of DNA viremia and follow-up
was complete with only three patients lost to follow-up
after 345–635 days. We were therefore able to provide a
complete picture of late-onset CMV disease including its
deleterious effects on the clinical outcome in the era of
6 months universal prophylaxis as practiced in a single
academic transplant center. Even with only 19 kidney graft
losses observed during the 5-year study period, the neg-
ative impact of late-onset CMV disease remains clearly
visible.
Major limitations of our study are related to its retrospec-
tive observational nature and its single center setting. The
diagnosis of late-onset CMV disease was based upon
Table 2: Clinical correlates of kidney graft loss
Death or graft loss Death-censored graft loss
HR 95% CI p HR 95% CI p
Late-onset CMV disease 2.95 1.15, 7.61 0.025 7.50 2.32, 24.3 < 0.001
Recipient age (years) 1.09 1.04, 1.14 < 0.001 NS
Baseline renal function 0.95 0.92, 0.98 0.004 0.94 0.90, 0.99 0.013
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clinical suspicions by individual physicians, thus there
might be some missing cases with subtle clinical symp-
toms and/or signs of CMV disease. On the other hand, a
sizable number of asymptomatic cases (8.8%) argues for
heightened awareness of such infection among clinicians
involved in the patient care. In addition, single center ex-
perience may not necessarily be generalized due to some
uniqueness of patient population and/or clinical practice
pattern. Finally, due to above reasons, a direct comparison
with other studies (clinical trial and/or other observational
studies) should not be made (4,9,25).
In conclusion, late-onset CMV disease continues to nega-
tively impact kidney transplant outcome despite a 6-month
low-dose VGCV prophylaxis. Investigations of novel preven-
tive approaches are urgently needed.
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